Your browser doesn't support javascript.
loading
Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153 152 middle-aged individuals.
Joseph, Philip G; Healey, Jeffrey S; Raina, Parminder; Connolly, Stuart J; Ibrahim, Quazi; Gupta, Rajeev; Avezum, Alvaro; Dans, Antonio L; Lopez-Jaramillo, Patricio; Yeates, Karen; Teo, Koon; Douma, Reuben; Bahonar, Ahmad; Chifamba, Jephat; Lanas, Fernando; Dagenais, Gilles R; Lear, Scott A; Kumar, Rajesh; Kengne, Andre P; Keskinler, Mirac; Mohan, Viswanathan; Mony, Prem; Alhabib, Khalid F; Huisman, Hugo; Iype, Thomas; Zatonska, Katarzyna; Ismail, Rosnah; Kazmi, Khawar; Rosengren, Annika; Rahman, Omar; Yusufali, Afzalhussein; Wei, Li; Orlandini, Andres; Islam, Shofiqul; Rangarajan, Sumathy; Yusuf, Salim.
Afiliación
  • Joseph PG; Population Health Research Institute, McMaster University, 237 Barton St East, Hamilton, Ontario L8L 2X2, Canada.
  • Healey JS; Population Health Research Institute, McMaster University, 237 Barton St East, Hamilton, Ontario L8L 2X2, Canada.
  • Raina P; Canadian Longitudinal Study of Aging, McMaster University, Hamilton, Ontario, Canada.
  • Connolly SJ; Population Health Research Institute, McMaster University, 237 Barton St East, Hamilton, Ontario L8L 2X2, Canada.
  • Ibrahim Q; Population Health Research Institute, McMaster University, 237 Barton St East, Hamilton, Ontario L8L 2X2, Canada.
  • Gupta R; Eternal Heart Care Centre and Research Institute, India.
  • Avezum A; Hospital Alemão Oswaldo Cruz and UNISA, São Paulo, Brazil.
  • Dans AL; Philippines General Hospital, Manila, Philippines.
  • Lopez-Jaramillo P; Masira Research Institute, Universidad de Santander (UDES), Bucaramanga, Colombia.
  • Yeates K; Queen's University, Kingston, Canada.
  • Teo K; Population Health Research Institute, McMaster University, 237 Barton St East, Hamilton, Ontario L8L 2X2, Canada.
  • Douma R; Population Health Research Institute, McMaster University, 237 Barton St East, Hamilton, Ontario L8L 2X2, Canada.
  • Bahonar A; Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Chifamba J; University of Zimbabwe, Department Of Physiology, Harare, Zimbabwe.
  • Lanas F; Universidad de La Frontera, Temuco, Chile.
  • Dagenais GR; Université Laval, Quebec, Canada.
  • Lear SA; Simon Fraser University, Burnaby, Canada.
  • Kumar R; Post Graduate Institute of Medical Education and Research (PGIMER) School of Public Health, Chandigarh, India.
  • Kengne AP; South African Medical Research Council, Pietermaritzburg, South Africa.
  • Keskinler M; Istanbul Goztepe Training and Research Hospital, Istanbul, Turkey.
  • Mohan V; Madras Diabetes Research Foundation, Chennai, India.
  • Mony P; St John's Medical College & Research Institute, Bengaluru, India.
  • Alhabib KF; Department of Cardiac Sciences, King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
  • Huisman H; Hypertension in Africa Research Team (HART), North-West University, Potchefstroom, South Africa.
  • Iype T; South African Medical Research Council: Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa.
  • Zatonska K; Government Medical College, Kerala, India.
  • Ismail R; Department of Social Medicine, Medical University of Wroclaw, Wroclaw, Poland.
  • Kazmi K; Universiti Kebangsaan, Selangor, Malaysia.
  • Rosengren A; Aga Khan University, Karachi, Pakistan.
  • Rahman O; Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Yusufali A; Independent University, Dhaka, Bangladesh.
  • Wei L; Hatta Hospital, Dubai Health Authority, Dubai, United Arab Emirates.
  • Orlandini A; Fuwai Hospital, National Center for Cardiovascular Disease, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
  • Islam S; Estudios Clínicos Latinoamérica (ECLA), Santa Fe, Argentina.
  • Rangarajan S; Population Health Research Institute, McMaster University, 237 Barton St East, Hamilton, Ontario L8L 2X2, Canada.
  • Yusuf S; Population Health Research Institute, McMaster University, 237 Barton St East, Hamilton, Ontario L8L 2X2, Canada.
Cardiovasc Res ; 117(6): 1523-1531, 2021 05 25.
Article en En | MEDLINE | ID: mdl-32777820
ABSTRACT

AIMS:

To compare the prevalence of electrocardiogram (ECG)-documented atrial fibrillation (or flutter) (AF) across eight regions of the world, and to examine antithrombotic use and clinical outcomes. METHODS AND

RESULTS:

Baseline ECGs were collected in 153 152 middle-aged participants (ages 35-70 years) to document AF in two community-based studies, spanning 20 countries. Medication use and clinical outcome data (mean follow-up of 7.4 years) were available in one cohort. Cross-sectional analyses were performed to document the prevalence of AF and medication use, and associations between AF and clinical events were examined prospectively. Mean age of participants was 52.1 years, and 57.7% were female. Age and sex-standardized prevalence of AF varied 12-fold between regions; with the highest in North America, Europe, China, and Southeast Asia (270-360 cases per 100 000 persons); and lowest in the Middle East, Africa, and South Asia (30-60 cases per 100 000 persons) (P < 0.001). Compared with low-income countries (LICs), AF prevalence was 7-fold higher in middle-income countries (MICs) and 11-fold higher in high-income countries (HICs) (P < 0.001). Differences in AF prevalence remained significant after adjusting for traditional AF risk factors. In LICs/MICs, 24% of participants with AF and a CHADS2 score ≥1 received antithrombotic therapy, compared with 85% in HICs. AF was associated with an increased risk of stroke [hazard ratio (HR) 2.29; 95% confidence interval (CI) 1.49-3.52] and death (HR 2.97; 95% CI 2.25-3.93); with similar rates in different countries grouped by income level.

CONCLUSIONS:

Large variations in AF prevalence occur in different regions and countries grouped by income level, but this is only partially explained by traditional AF risk factors. Antithrombotic therapy is infrequently used in poorer countries despite the high risk of stroke associated with AF.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibrilación Atrial / Aleteo Atrial / Pautas de la Práctica en Medicina / Salud Global / Disparidades en Atención de Salud / Fibrinolíticos Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cardiovasc Res Año: 2021 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibrilación Atrial / Aleteo Atrial / Pautas de la Práctica en Medicina / Salud Global / Disparidades en Atención de Salud / Fibrinolíticos Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cardiovasc Res Año: 2021 Tipo del documento: Article País de afiliación: Canadá